Publication:
Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey

dc.contributor.authorSağ, Saim
dc.contributor.authorKaderli, Aysel Aydın
dc.contributor.authorYıldız, Abdülmecit
dc.contributor.authorGül, Bülent Cuma
dc.contributor.authorÖzdemir, Bülent
dc.contributor.authorBaran, İbrahim
dc.contributor.authorGüllülü, Sümeyye
dc.contributor.authorAydınlar, Ali
dc.contributor.authorÇavuşoğlu, Yüksel
dc.contributor.buuauthorSağ, Saim
dc.contributor.buuauthorKaderli, Aysel Aydın
dc.contributor.buuauthorYILDIZ, ABDULMECİT
dc.contributor.buuauthorGÜL, CUMA BÜLENT
dc.contributor.buuauthorÖZDEMİR, BÜLENT
dc.contributor.buuauthorBaran, İbrahim
dc.contributor.buuauthorGÜLLÜLÜ, NAZMİYE SÜMEYYE
dc.contributor.buuauthorAYDINLAR, ALİ
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentKardiyoloji Ana Bilim Dalı
dc.contributor.researcheridAAI-6632-2021
dc.contributor.researcheridAAW-9185-2020
dc.contributor.researcheridA-7063-2018
dc.contributor.researcheridCXL-7581-2022
dc.contributor.researcheridHIG-9032-2022
dc.contributor.researcheridJHE-3353-2023
dc.contributor.researcheridCDA-1396-2022
dc.contributor.researcheridJGR-6552-2023
dc.date.accessioned2024-11-20T10:37:31Z
dc.date.available2024-11-20T10:37:31Z
dc.date.issued2017-07-01
dc.description.abstractObjective: The aim of the present study was to assess the efficacy and safety of tolvaptan for severe hyponatremia (SH) in hypervolemic heart failure (HF) patients within daily clinical practice.Methods: We restrospectively reviewed our database on tolvaptan as an add-on treatment in hypervolemic patients admitted to our clinic due to deterioration of HF and having hyponatremia resistant to standard therapy. Severe hyponatremia was defined as serum sodium concentration <= 125 mEq/L. The database included demographic, clinical, laboratory, and echocardiographic findings on admission, and numerous outcome measures for oral tolvaptan treatment were used to assess its efficacy and safety.Results: The study group consisted of 56 hypervolemic HF patients with severe hyponatremia (25 female and 31 male) with mean age of 66 years. All patients received a single dose of tolvaptan 15 mg daily for an average of 3.2 days due to severe hyponatremia. Sodium and potassium concentrations, fluid intake, and urine volume increased (p<0.0001, p=0.037, p<0.0001, and p<0.0001, respectively), whereas furosemide dosage, body weight, heart rate, systolic and diastolic blood pressure, and New York Heart Association class decreased significantly in response to tolvaptan treatment, without a rise in serum creatinine or urea concentrations (p<0.0001, p<0.0001, p=0.001, p<0.049, p<0.009 ve p=0.001, respectively).Conclusion: In this retrospective, single-centered study conducted in a small group of Turkish patients, short-term treatment with low-dose tolvaptan added to standard therapy of hypervolemic HF patients with severe hyponatremia was well tolerated with a low rate of major side effects and was effective in correcting severe hyponatremia.
dc.identifier.doi10.5543/tkda.2017.80026
dc.identifier.endpage425
dc.identifier.issn1016-5169
dc.identifier.issue5
dc.identifier.startpage415
dc.identifier.urihttps://doi.org/10.5543/tkda.2017.80026
dc.identifier.urihttps://archivestsc.com/jvi.aspx?un=TKDA-80026
dc.identifier.urihttps://hdl.handle.net/11452/48206
dc.identifier.volume45
dc.identifier.wos000411505100005
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherKare Yayınevi
dc.relation.journalTürk Kardiyoloji Derneği Arsivi-Archives of The Turkish Society of Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectReduced ejection fraction
dc.subjectVasopressin v-2-receptor antagonist
dc.subjectEverest trial
dc.subjectPrognostic value
dc.subjectDouble-blind
dc.subjectInsights
dc.subjectRegistry
dc.subjectRationale
dc.subjectBlockade
dc.subjectOutcomes
dc.subjectAquaretic treatment
dc.subjectCongestive heart failure
dc.subjectHyponatremia
dc.subjectTolvaptan
dc.subjectCardiovascular system & cardiology
dc.titleUse of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Kardiyoloji Ana Bilim Dalı
local.contributor.departmentTıp Fakültesi/Nefroloji Ana Bilim Dalı
relation.isAuthorOfPublicatione0f20ddb-a439-4c4a-b87e-d468370abf60
relation.isAuthorOfPublication238d3aec-d833-48a1-b2c7-867f7fe94d52
relation.isAuthorOfPublicationc653a7c1-4ead-46da-83e5-de7378a3726d
relation.isAuthorOfPublication77d29b17-5aa2-4052-b890-842f658dd83b
relation.isAuthorOfPublication2fb1abc1-b647-4b1a-ac41-5cef9ff456c3
relation.isAuthorOfPublication.latestForDiscoverye0f20ddb-a439-4c4a-b87e-d468370abf60

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Sag_vd_2017.pdf
Size:
368.55 KB
Format:
Adobe Portable Document Format

Collections